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Abstracts A77
Americans participants in the later stages of CKD may be associated with lack of health 
care access/ socio-economic factors. The proportion of population suffering from 
hypertension and diabetes increased signiﬁcantly from stage 1 to stage 5 along with 
marked racial disparities in the higher stages of CKD. Markers such as Vitamin D 
deﬁciency, Hypertension & serum creatinine levels can be better monitored by regular 
blood tests and prove to be effective early indicators in the progression of CKD.
URINARY/KIDNEY DISORDERS – Cost Studies
PUK6
FIVE-YEAR BUDGET IMPACT ANALYSIS OF ONCE-DAILY VERSUS 
TWICE-DAILY TACROLIMUS, IN PATIENTS UNDERGOING RENAL 
TRANSPLANT IN THE UNITED KINGDOM
Sidhu M1, Lees L2, Warner J2
1Astellas Pharma Europe Ltd, Staines, Middlesex, UK, 2Abacus International, Bicester, 
Oxfordshire, UK
OBJECTIVES: Non-adherence to immunosuppressants increases risk of late acute 
rejection (AR) episodes, a known predictor of graft loss, which is associated with 
re-transplantations, dialysis and increased mortality. Once-daily immunosuppressant 
formulations demonstrate higher patient adherence than multiple daily dose therapies 
and may lead to fewer AR episodes and graft losses. A model was constructed to 
estimate the ﬁve-year impact of potentially improved adherence in new renal trans-
plant recipients receiving once- rather than twice-daily tacrolimus. METHODS: The 
increased potential for sufﬁcient adherence with once-daily immunosuppressants, 
versus twice-daily, is reported as an odds ratio (OR) of 2.35 (published literature). 
The model uses a probability of sufﬁcient adherence of 74% with once-daily tac-
rolimus, determined from an assumed adherence for twice-daily tacrolimus of 55% 
and OR for adherence with once- versus twice-daily therapy. Increased adherence is 
assumed to improve consistency in tacrolimus exposure, reducing AR each year post-
transplant and improving graft survival. Sufﬁcient levels of expected adherence with 
once- and twice-daily tacrolimus are used to model ﬁve-year survival rates for: AR 
(sufﬁciently-adherent versus non-sufﬁciently-adherent patients); graft survival (no pre-
vious AR versus previous AR); patient survival (functioning graft versus dialysis). Drug 
costs include tacrolimus; co-prescribed therapies (IV and oral prednisolone and oral 
mycophenolate mofetil). Other resource use and costs considered include management 
of AR; dialysis after graft loss; re-transplantation. RESULTS: Over ﬁve years, assum-
ing 100 new renal transplant recipients annually, once-daily tacrolimus is associated 
with fewer AR episodes than twice-daily (8.4 and 10.5, respectively), due to improved 
sufﬁcient adherence. Once-daily tacrolimus yields cumulative cost savings of £104,534, 
including savings in drug acquisition (£69,180); management of AR (£22,837); re-
transplantation (£417); dialysis (£13,631). CONCLUSIONS: Use of once- rather than 
twice-daily tacrolimus reduces incidence of AR and could yield clinical improvements 
and cost savings over ﬁve-years.
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IMMUNOSUPPRESSANT THERAPY PATTERNS AND ITS COSTS IN POST 
KIDNEY TRANSPLANT PATIENTS IN THE NATIONAL TRANSPLANT 
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OBJECTIVES: Immunosuppressive drugs (IS) are used in combination/schemes to 
achieve optimal regimen of immunosupression, increasing graft and recipient survival 
rates in post kidney transplant patients. The aim of this study is to determine immu-
nosuppressant treatment patterns and associated costs in kidney transplant patients 
from the Brazilian National Transplant Program. METHODS: A review of the entire 
government administrative claim database (Outpatient Information System – SIA/
DATASUS) was conducted from 2005 to 2008, to determine yearly expenses (in 2008 
USD) with each IS combination. In order to assess the dynamics of the combinations 
used, a subset of this population, all patients from 7 hospitals who underwent kidney 
transplantation in 2004, was followed from January 2005 to December 2007 to 
estimate calcineurin inhibitors (CNI) switching rate and treatment adherence in terms 
of 24-month medication possession ratio (MPR). RESULTS: Analysis of the entire 
database reveals that overall IS expenses in kidney transplant patients more than 
doubled, from US$62,429,359 in 2005 to US$126,874,381 in 2008, mostly due to an 
increase in both treatment volume and costs from 2006 to 2007. From 2005 to 2007, 
monthly treatment volume increased 14.7% for cyclosporine and 62.9% for tac-
rolimus, whereas costs increased 3.2% for cyclosporine and 93.1% for tacrolimus. 
The highest ﬁnancially impacting combination per CNI were tacrolimus plus myco-
phenolate sodium (US$37,329,606 in 2008), and cyclosporine plus mycophenolate 
sodium (US$10,163,990 in 2008). A total of 540 patients were eligible for the sub-
population analysis. CNI therapy switch rate, from tacrolimus to cyclosporine or 
vice-versa was 4.3% (n = 185). MPR for CNIs was 73.7% (n = 224; SD = 21.7%). 
CONCLUSIONS: From 2005 to 2008, IS drugs expenses in post kidney transplant 
patients substantially increased in Brazil. Low CNI switching rates suggests that de 
novo patients are the main target population for newer CNIs. The poor drug adher-
ence detected is an important point of concern.
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ERYTHROPOIESIS-STIMULATING AGENTS UTILIZATION AND COSTS 
IN PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS 
FROM TWO LARGE CLAIMS DATABASES
Lafeuille MH1, Bailey RA2, Laliberté F1, Senbetta M2, Blacksmith A1, Lefebvre P1
1Groupe d’analyse, Ltée, Montreal, QC, Canada, 2Centocor Ortho Biotech Services, LLC, 
Horsham, PA, USA
OBJECTIVES: This study evaluated recent erythropoiesis-stimulating agent (ESA) 
utilization and costs from 2 large health insurance claims databases in chronic kidney 
disease (CKD) patients not on dialysis. METHODS: An analysis of recent medical 
claims from the Ingenix IMPACT (January 2006-March 2009) and Medicare 5% 
(January 2005-December 2007) databases was conducted. Patients ≥18 years, newly 
initiated on epoetin alfa (EPO) or darbepoetin alfa (DARB), with ≥1 claim for CKD 
and ≥2 ESA claims were included. Patients diagnosed with cancer, receiving chemo-
therapy or dialysis, or receiving both agents were excluded. Mean cumulative ESA 
dose was used to calculate drug cost (using October 2009 wholesale acquisition cost) 
and dose ratio (Units EPO: mcg DARB). Multivariate analysis was also conducted to 
assess adjusted cost differences between the two agents. RESULTS: A total of 4,678 
ESA-treated patients were identiﬁed (IMPACT—EPO: 991, DARB: 689; Medicare—
EPO: 1,788, DARB 1,210). Age and gender distributions were similar between 
the 2 groups (Mean age: IMPACT: 63.9 vs. 63.2 yrs; Medicare: 74.7 vs. 74.2 yrs, P 
= NS; % women: IMPACT: 49% vs. 54%; Medicare 59% vs. 62%, P = NS). ESA 
treatment duration was also similar for EPO and DARB patients. The mean cumulative 
dose [SD] was 164,786 [175,453] and 244,718 [304,839] Units for EPO and 
694 [690] and 989 [1,118] mcg for DARB, resulting in dose ratios of 237:1 and 247:1 
for IMPACT and Medicare data, respectively. Based on the recent utilization of 
ESAs, cumulative cost was 44% and 38% higher for DARB than EPO (IMPACT—
EPO $2380; DARB $3427; Medicare—EPO $3534; DARB $4888). After adjusting 
for covariates, cumulative drug costs remained signiﬁcantly higher for DARB. 
CONCLUSIONS: Based on large health insurance claims databases, this observational 
study of recent ESA utilization in CKD patients not on dialysis reported dose 
ratios of 237:1 and 247:1 and cost premiums of 44% and 38% associated with 
DARB.
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OBJECTIVES: This study compared drug utilization patterns and associated costs as 
well as dosing trends over time in patients with chronic kidney disease (CKD) not on 
dialysis receiving epoetin alfa (EPO) or darbepoetin alfa (DARB) through a pharmacy 
beneﬁt. METHODS: An analysis of pharmacy claims between July 2002 and March 
2009 from the Ingenix IMPACT database was conducted. Patients ≥18 years, newly 
initiated on erythropoiesis-stimulating agents (ESAs), with ≥1 claim for CKD, and ≥1 
ESA pharmacy claim were included. Patients diagnosed with cancer, receiving chemo-
therapy or dialysis, or receiving both agents were excluded. Mean cumulative ESA 
dose was used to calculate drug cost (using 10/2009 wholesale acquisition cost) and 
dose ratio (Units EPO: mcg DARB). Average weighted weekly ESA dose was calculated 
during the treatment episode to assess ESA utilization trends over time. Multivariate 
analysis was also conducted. RESULTS: A total of 4,202 ESA-treated patients were 
identiﬁed (EPO 3,111; DARB 1,091). EPO patients were slightly older (60.1 vs. 57.0, 
P < .001) with a higher Charlson Comorbidity Index (1.68 vs 1.44, P < .001). Mean 
[SD] cumulative dose was 219,060 [236,830] Units for EPO and 818 [956] mcg for 
DARB, resulting in a dose ratio of 268:1 (Units EPO: mcg DARB). The corresponding 
drug cost was 28% higher for DARB than EPO ($3163 vs. $4039, P < .001). 
From 2002 to 2009, a decreasing trend was observed in semi-annual mean weekly 
doses of ESAs [EPO: 17,053 to 13,674 Units (25% decrease); DARB: 63 to 51 mcg 
(20% decrease)]. After adjusting for potential confounding factors, the DARB cost 
premium and the decreasing weekly ESA dosing trend over time remained signiﬁcant. 
CONCLUSIONS: This study of CKD patients not on dialysis receiving ESAs through 
pharmacy beneﬁts reported signiﬁcantly higher drug costs in the DARB group 
compared with the EPO group and a decreasing ESA dosing trend during the 7-year 
study period.
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OBJECTIVES: The objective of this study is to evaluate hospitalizations, outpatient 
services and medication use in the ﬁrst year of dialysis associated with pre-dialysis 
treatment with paricalcitol compared to no predialysis vitamin D receptor (VDR) 
activator use in chronic kidney disease (CKD) patients with SHPT. METHODS: A 
matched cohort analysis was conducted in 154 hemodialysis patients comparing uti-
lization outcomes of predialysis use of paricalcitol compared to no VDR activator 
treatment, using the Medstat™ administrative claims database from 2000–2007. 
Patients were matched using propensity scoring for age, gender, Charlson co-morbid-
ity Index, and pre-index total costs. Multivariate models adjusted for age, gender, 
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insurance, physician type, region, pre-dialysis co-morbidities, and pre-dialysis costs 
were used to evaluate the impact of pre-dialysis paricalcitol treatment on hospitaliza-
tions, outpatient services, and medication use in ﬁrst year of dialysis. RESULTS: 
Multivariable analysis demonstrated predialysis paricalcitol use was associated 
with statistically signiﬁcant reductions in all-cause hospitalizations (0.806, 95%CI: 
0.684–0.950), all-cause outpatient services (0.953, 95%CI: 0.933–0.973) and CKD-
related hospitalizations (0.780, 95% CI: 0.635 – 0.958); CKD-related outpatient 
visits (0.962, 95% CI: 0.938–0.987); and CKD-related medications (0.922, 95% CI: 
0.852–0.996) in the ﬁrst year of dialysis compared with no predialysis VDR activator 
treatment. CONCLUSIONS: Paricalcitol treatment for SHPT prior to dialysis is 
associated with fewer CKD-related medications; and all-cause and CKD-related out-
patient services and hospitalizations in the ﬁrst year of dialysis compared to no VDR 
activator treatment. Payers should consider these ﬁndings when make coverage deci-
sions regarding the use of paricalcitol. Further studies are needed to conﬁrm these 
results.
PUK11
COST-EFFECTIVENESS ANALYSIS OF DUTASTERIDE,TAMSULOSIN 
AND COMBINATION THERAPY IN THE TREATMENT OF BENIGN 
PROSTATIC HYPERPLASIA
Bang SI, Hay J
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: The Combination of Avodart® and Tamsulosin (CombAT) study 
shows that combination therapy provides a signiﬁcantly greater degree of beneﬁt than 
tamsulosin or dutasteride monotherapy in the treatment of moderate to severe benign 
prostatic hyperplasia (BPH). The objective of this study was to assess the cost-effec-
tiveness of combination therapy with tamsulosin and dutasteride relative to either of 
monotherapies using recent information from the CombAT study. METHODS: A 
decision analytic model was constructed using a Markov model and a 1-year cycle 
time to estimate the clinical and cost consequences of tamsulosin, dutasteride, and 
combination therapy. Analyses were conducted for a 20-year time frame from the 
societal perspective. All costs are presented in 2009 US dollars, and costs and outcomes 
were discounted at a rate of 3% per year. Outcomes were expressed in terms of the 
incremental cost-effectiveness ratio (ICER), deﬁned as the ratio of additional costs to 
additional QALYs. Sensitivity analyses were conducted on model probabilities, cost 
estimates, utility values and the discount rate. RESULTS: At both moderate and severe 
symptom levels, tamsulosin was dominated by dutasteride, that is, more costly and 
less effective than dutasteride. Compared to dutasteride, combination therapy was 
more expensive but more effective with the ICERs of $197,625 for moderate symp-
toms and $241,032 for severe symptoms. However, considering a societal cost-effec-
tiveness threshold of $150,000 per QALY, combination therapy was not cost-effective 
compared to dutasteride. In most sensitivity analyses, these results were not sensitive 
to changes in model parameters. CONCLUSIONS: This study showed that tamsulosin 
was more costly and less effective than dutasteride, and the ICERs for combination 
therapy compared to dutasteride were higher than the cost-effectiveness threshold. 
Therefore, combination therapy is not cost-effective relative to dutasteride for 
moderate-to-severe BPH patients.
PUK12
ECONOMIC EVALUATION ON THE USE OF OXYBUTYNIN, 
TOLTERODINE, AND SOLIFENACIN IN PATIENTS WITH  
HYPERACTIVE BLADDER
De Lago Acosta A1, Salinas G2, Idrovo J3, Zapata L4, Alanís A1, Rico I5
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OBJECTIVES: Hyperactive Bladder (HB) is a common, debilitating condition with a 
considerable negative impact on quality of life. The cost-effectiveness (CE) of three 
medications was evaluated for the treatment of patients with Hyperactive Bladder 
from the Mexican Institute of Social Security (IMSS) perspective. METHODS: CE 
analysis from the perspective of the service provider (IMSS). Since it is a chronic disease 
with different stages, a Markov model with monthly cycles in a 12-month temporal 
horizon was developed. Only direct medical costs were used in the analysis. Direct 
medical costs were estimated on a sample of patient ﬁles in two IMSS medical units. 
Criteria for inclusion was patients with more than 6 months of treatment. The effec-
tiveness measurement was taken from literature and was deﬁned as the percentage of 
patients that did not present symptoms of incontinence. Univariated and probabilistic 
sensitivity analyses were performed. RESULTS: The oxybutynin treatment reﬂected 
the lowest expected cost per patient treated for hyperactive bladder, US$545 (1 USD 
= 13.5MXN); followed by the solifenacin and tolterodine treatments, with a cost of 
US$680 and US$1,135, respectively. As for the effectiveness measurement, the percent-
age of patients that did not present incontinence within the temporal horizon of analysis 
was: with tolterodine 2.76%, with oxybutynin 7.11% and with solifenacin 7.46%. 
Therefore, cost effectiveness ratios interpreted as the cost per percentage point of 
patients that did not present HB are: oxybuynin US$77, solifenacin US$91 and tol-
terodine US$411. The incremental cost effectiveness analysis indicates that tolterodine 
is a dominated alternative and that oxybutynin and solifenacin are positioned 
within the efﬁciency line. Nonetheless, when conducting the probabilistic analysis, it 
was found that with US$411 available, a solifenacin treatment would be more cost 
effective for the institution. CONCLUSIONS: From an institutional perspective, solif-
enacine is a cost-effective alternative for treating patients with HB in the Mexican 
context.
PUK13
THE COST-EFFECTIVENESS OF EARLY SURGERY, ADDING BIOPSY, 
AND WATCHFUL WAITING IN THE MANAGEMENT OF SMALL SOLID 
RENAL MASSES: EVIDENCE FROM A MARKOV MODEL
Yu J1, Heilbrun M1, Smith K2, Zagoria R3
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OBJECTIVES: To compare the relative cost-effectiveness of three clinical strategies 
for managing T1a tumor (4 cm or smaller and limited to the kidney): early surgery 
upon detection of the tumor, adding percutaneous biopsy prior to surgery, and watch-
ful waiting (WW) (monitor with computerized tomography every 6 months until the 
growth is greater than 2mm per year). METHODS: A Markov decision tree was used 
to estimate the expected survival in quality-adjusted life years (QALYs) and incremen-
tal cost-effectiveness (ICER) for each strategy from a societal perspective, based on 
literature-derived estimates for the probabilities and costs of different outcomes. 
Multiple one-way and probabilistic sensitivity analysis were conducted to examine the 
robustness of the results. RESULTS: In the base-case, adding biopsy before surgery 
improved survival by 0.018 QALYs compared with immediate surgery, at an incre-
mental cost of $55,244/QALY, while the ICER of WW relative to surgery was 
$11,712/QALY. In the base-case, percutaneous biopsy is more expensive and less 
effective than WW. The treatment decision was most sensitive to variation of the 
degree of tumor growth that triggers surgery, utility of living with a mass during WW, 
and the probability of diagnostic biopsy for benign tumors. Choice of WW versus 
surgery critically depends on patients’ preferences for tumor removal and the risk of 
recurrence post surgery. In probabilistic sensitivity analysis, surgery was the most 
favored strategy when the willingness to pay (WTP) is less than $10,000/QALY. WW 
is favored as WTP increases beyond $10,000/QALY, and biopsy was favored over 
surgery when WTP is > $60,000. CONCLUSIONS: Although WW results in the 
highest life-time utility, the favorability of WW depends on patients’ preferences for 
living with a possibly malignant mass and natural history of watched masses during 
surveillance, which are poorly understood. Biopsy would be favored if its costs 
decrease and diagnostic certainty increases in the future.
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CHALLENGES IN ASSESSING COST-EFFECTIVENESS OF THERAPIES 
FOR DIALYSIS PATIENTS: A CASE STUDY OF SEVELAMER FOR THE 
TREATMENT OF HYPERPHOSPHATEMIA
Grima D1, Mendelssohn D2, Airia P1, Dunn E3, Bernard L1
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OBJECTIVES: Therapies that extend the lives of dialysis patients can not demonstrate 
cost-effectiveness if dialysis costs are included. This study examined the cost-effective-
ness of sevelamer versus calcium-based binders (CBBs) as treatment for hyperphos-
phatemia in dialysis patients and, within this context, the suitability of the inclusion 
of dialysis costs. METHODS: A Markov model estimated life years, incremental cost 
per life year gained (LYG) and incremental quality-adjusted life year gained (QALYG). 
Treatment-speciﬁc survival was derived from the Dialysis Clinical Outcomes Revisited 
(DCOR) study and extrapolated using a Weibull regression model. The base case 
analysis used resource use and survival data for DCOR patients ≥65 years combined 
with Canadian unit costs and utility weights from published literature. Dialysis costs 
were excluded from the base case analysis, as dialysis use is unrelated to phosphate 
binder choice. Analyses were conducted for a 10-year time horizon using the Alberta 
Health Care System perspective, with costs and outcomes discounted at 5% per year. 
RESULTS: Compared with CBBs, sevelamer resulted in a gain of 1.02 LYs and 
0.62 QALYs/ patient (discounted) producing ratios of $20,847/LYG and $34,175/
QALYG. Over a lifetime horizon, the cost/LYG and cost/QALYG were $23,804 and 
$39,022, respectively. Inclusion of dialysis costs resulted in ratios above $90,000/LYG 
and $150,000/QALYG. CONCLUSIONS: The study highlights the challenges associ-
ated with assessing funding of therapies that extend life in dialysis patients and dis-
cusses the applicability of dialysis costs in such situations. It found that sevelamer 
offers good value for money compared to CBBs in the treatment of hyperphosphatemia 
in patients ≥65 years old receiving dialysis.
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COST-EFFECTIVENESS ANALYSIS OF THREE MONTHS TREATMENT 
WITH FESOTERODINE COMPARED TO GENERIC OXYBUTYNIN 
EXTENDED-RELEASE IN WOMEN WITH URINARY INCONTINENCE 
FROM A THIRD PARTY PAYER PERSPECTIVE
Blaser DA1, Kohn MJ2, Ousterhout M1
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OBJECTIVES: Six pharmacological agents are FDA-approved to treat urinary incon-
tinence, a condition that has economic costs of $19 billion US dollars per year. This 
study compares the recently FDA-approved fesoterodine to generic oxybutynin 
extended-release (ER) to identify which agent is more cost-effective in the treatment 
of urinary incontinence for three months in women over age 60 from the third party 
payer perspective. METHODS: A search was conducted using the MEDLINE Data-
base from 1980–2009 for the terms “oxybutynin,” “fesoterodine,” “randomized 
controlled trial,” and “urinary incontinence.” Five articles evaluating clinical improve-
ment among a predominantly female population were identiﬁed for inclusion. For the 
purpose of this analysis, an effectively treated patient was deﬁned as a patient dem-
onstrating a decrease of 14 or more episodes per week of each of the following: urge 
